Fig. 3From: Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrencesCost-effectiveness Acceptability Curve. Figure 3 shows the probability of an intervention being the most cost-effective alternative at various willingness-to to-pay thresholds, given the uncertainty surrounding inputsBack to article page